FATE - Fate Therapeutics EPS misses by $0.22 beats on revenue February, 24 2021 04:05 PM Fate Therapeutics Inc. Fate Therapeutics (FATE): Q4 GAAP EPS of -$0.61 misses by $0.22.Revenue of $15.9M (+467.9% Y/Y) beats by $10.85M.Press Release For further details see: Fate Therapeutics EPS misses by $0.22, beats on revenue